We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Biotech Presents Sustainable Lab Solutions with Unlimited Possibilities at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: Getein’s POCT testing solutions meet the different needs of laboratory detection (Photo courtesy of Getein Biotech)
Image: Getein’s POCT testing solutions meet the different needs of laboratory detection (Photo courtesy of Getein Biotech)

Getein Biotech, Inc. (Nanjing, China) is presenting its sustainable diagnostic solutions that offer unlimited possibilities for laboratories at the 2022 AACC Clinical Lab Expo.

AT AACC 2022, Getein will exhibit its range of POCT immunofluorescence quantitative analyzers, including the Getein1160, Getein1180, Getein1200 and Getein1600. These immunofluorescence quantitative analyzers automate the detection and quantification of markers for cardiovascular diseases, renal diseases, inflammation, fertility, diabetes mellitus, bone metabolism, tumor, and thyroid in biological samples. Getein is also showcasing the MAGICL6000 chemiluminescence immunoassay analyzer that automates the detection and quantification of markers for thyroid disease, inflammation, cardiac diseases, fertility, diabetes mellitus, bone metabolism, tumor, infectious disease, anemia, and immune globulin by analyzing human serum, plasma, whole blood and urine samples.

In addition, Getein will exhibit the fully automated CM-400 clinical chemistry analyzer for the quantitative analysis of chemical components in human serum, plasma, whole blood, urine, and cerebrospinal liquid samples. CM-400 is characterized by open reagents, discrete system, emergency priority, random access and an external computer. The analyzer consists of the main instrument and the computer with the main instrument composed of an optical system, reaction system, sample adding system, reagent adding system, cleaning system and mixing system, with an optional electrolyte module.

Getein is also highlighting the BHA-3000 and BHA-5000 automatic hematology analyzers that provide quantitative analysis of a patient's blood components at high speed with accuracy, alongside the XN06 semi-automated blood coagulation analyzer for testing four routine clotting test items, namely PT, TT, APTT and FIB. Getein will demonstrate its One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) for the qualitative detection of SARS-CoV-2 antigens in human nasal swab samples. The test is suitable for medical laypersons as a self-test at home or at work. Getein provides a comprehensive range of COVID-19 testing solutions, including neutralizing antibody tests, antigen tests and IgM/IgG antibody tests. Getein also offers the Monkeypox Virus Real-time PCR Kit for the qualitative detection of MPV in serum or lesion exudate samples.
 

Related Links:
Getein Biotech, Inc. 

New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
HSV-1 Test
Herpes Simplex Virus 1 Test
New
Cytomegalovirus Assay
Alethia CMV

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.